Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Efficacy and Safety of a newly registered Artemisinin-Based Combination (Pyronaridine-Artesunate -PYRAMAX®) for the treatment of uncomplicated malaria in African pregnant women - Extended

Descripción del proyecto

Nuevo tratamiento antipalúdico para embarazadas en África

La evaluación de un nuevo tratamiento antipalúdico para embarazadas en África ha sufrido retrasos. El proyecto financiado con fondos europeos PYRAPREG, que había puesto en marcha esa evaluación, se vio obligado a interrumpirla debido a la pandemia de COVID-19. Ahora, el proyecto europeo PYRAPREG-Extended pretende concluir el estudio de PYRAPREG. El plazo ampliado incluye seis meses para el análisis de muestras, el control de calidad, la limpieza de datos y el análisis estadístico. Se prevé que el informe final esté listo para febrero de 2025. En el proyecto también se depurarán datos farmacocinéticos, que después se combinarán con datos clínicos de eficacia y toxicidad, y se llevarán a cabo actividades de modelización farmacodinámica y farmacocinética poblacional durante nueve meses. El proyecto apoyará asimismo la finalización de las investigaciones de los estudiantes participantes.

Objetivo

PYRAPREG-extended aims to complete PYRAPREG project (PACTR 202011812241529) that determines efficacy and safety of Pyronaridine-Artesunate (PA) - PYRAMAX®, a newly registered Artemisinin-Based Combination, to treat uncomplicated malaria in African pregnant women, and to provide the necessary information to include this treatment in guidelines for management of malaria during pregnancy. The work includes a one year follow-up of children born to women included in the trial and pharmacokinetic (PK) sub-study. In addition, this project comprises an extensive capacity building component, including the training of PhD students. PYRAPREG activities started 1 March 2019, and were expected to be completed 28 February 2024. Intense site preparations were completed, but just before start of recruitment, COVID-19 pandemic started and significantly delayed trial implementation. Participant recruitment started early 2021 and was completed in 2023, with last delivery expected in Q3 2023. Final 1-year visit of children born to women included in the trial will occur mid-2024. Furthermore, sample analysis for QC, data cleaning and statistical analysis takes another 6 months to completion, allowing final report submission 2 months later (Feb. 2025). PK component was delayed due to late initiation of recruitment for the PK cohorts of patients. Last patient recruitment in the PK cohort is ongoing and PK sampling will finish Q3 2023. Participants follow up continues until all women delivered and all babies have reached the age of 1 year. PK bioanalysis is expected to be finished by February 2024. PK data cleaning and merging with clinical efficacy and toxicity data followed by population PK and pharmacodynamic modelling activities will then be initiated which will take around 9 months, leading up to a PK report by February 2025. PhDs encountered delays: students could not travel for training, and data collection for their studies was delayed and will be completed in PYRYPREG-extended.

Ámbito científico (EuroSciVoc)

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) HORIZON-JU-GH-EDCTP3-2023-01

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

STICHTING AMSTERDAM UMC
Aportación neta de la UEn
€ 301 141,25
Coste total
€ 301 141,25

Participantes (6)

Socios (1)